Ultralow-Dose IL 10–Expressing CAR T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Дата публикации: 23-07-2026 00:00:00

This nonrandomized clinical trial examines the safety and efficacy of interleukin-10–expressing CD19 chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Prognostic factors and an exploratory risk stratification model in newly diagnosed Pola-R-CHP-treated diffuse large B-cell lymphoma: A real-world retrospective cohort analysis	0	23.54	20-08-2026
2	Immune Checkpoint Inhibitors for Child-Pugh B Hepatocellular Carcinoma	0	11.22	01-10-2023
3	Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma	0	5.96	30-07-2026
4	Reproducing comparative therapeutic efficacy in relapsed refractory multiple myeloma using an external control arm derived from historical clinical trial data	0	5	14-07-2026
5	Intermittent reduced-dose methotrexate enabled continuation of induction therapy despite severe delayed methotrexate elimination in primary central nervous system lymphoma: a case report	0	5	16-07-2026
6	Individualized Stereotactic Ablative Radiotherapy for Lung Tumors	0	6.6	01-11-2023
7	Classic Hodgkin Lymphoma: A Review	0	7.97	03-08-2026
8	Предоперационная иммунотерапия на 10% повышает шансы выживания при раке легких	0	0	02-06-2025
9	First-in-human immunotherapy more than doubles progression-free survival in glioblastoma patients	7	8	10-07-2026
10	Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases	0	7	03-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 14.62. Источник: jamanetwork.com.